Effects of combined siRNA-TR and -TERT on telomerase activity and growth of bladder transitional cell cancer BIU-87 cells

  • Wen Cheng (程 文)
  • Zhifeng Wei (位志峰)
  • Jianping Gao (高建平)Email author
  • Zhengyu Zhang (张征宇)
  • Jingping Ge (葛京平)
  • Kangzhen Jing (景抗震)
  • Feng Xu (徐 锋)
  • Peng Xie (解 鹏)


The effects of combined RNA interference (RNAi) of human telomerase RNA (hTR) and human telomerase reverse transcriptase (hTERT) genes on telomerase activity in a bladder cancer cell line (BIU-87 cells) were investigated by using gene chip technology in vitro with an attempt to evaluate the role of RNAi in the gene therapy of bladder transitional cell cancer (BTCC). Three TR-specific double-stranded small interfering RNAs (siRNAs) and three TERT-specific double-stranded siRNAs were designed to target different regions of TR and TERT mRNA. The phTR-siRNA, phTERT-siRNA, and the combination of both plasmids phTR+phTERT-siRNA were transfected into BIU-87 cells. The expression of hTR and hTERT mRNA was detected by quantitative fluorescent reverse transcription-polymerase chain reaction, and a telomeric repeat amplification protocol was applied to detect telomerase activity. Growth inhibition of BIU-87 cells was measured by MTT assay. Gene chip analysis was performed to evaluate the effects of the combined RNAi of hTR+hTERT genes on telomerase activity and growth of BIU-87 cells in vitro. The results showed that the expression of hTERT and hTR mRNA was inhibited by pRNAT-hTERT-III, pRNAT-hTR-III, and pRNAT-hTR-III+hTERT-III in BIU-87 cells. The inhibition efficiency of pRNAT-hTERT-III, pRNAT-hTR-III, pRNAT-hTERT-III+pRNAT-hTR-III was 67% for TERT mRNA, 41% for TR mRNA, 57% for TR mRNA and 70% for TERT mRNA in BIU-87 cells respectively. The growth of BIU-87 cells was inhibited and telomerase activity was considerably decreased, especially in the cells treated with combined RNAi-hTR and -hTERT. Gene chip analysis revealed that 21 genes were down-regulated (ATM, BAX, BCL2, BCL2L1, BIRC5, CD44, CTNNB1, E2F1, JUN, MCAM, MTA1, MYC, NFKB1, NFKBIA, NME4, PNN, PNN, SERPINE1, THBS1, TNFRSF1A, and UCC1). The results indicated that hTR-siRNA and hTERT-siRNA, especially their combination, siRNA hTR+hTERT, specifically and effectively suppressed the expression of both hTR and hTERT mRNA and telomerase activity. Molecular biological mechanism by which combined siRNA-TR and -TERT inhibited telomerase activity and growth of BIU-87 cells in vitro may involve the down-regulation of the 21 genes.

Key words

human telomerase reverse transcriptase combined RNAi hTR gene hTERT gene transitional cell bladder cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nakatsukasa H, Onishi T, Kaneyoshi T, et al. Expression of telomerase-associated protein 1 and telomerase reverse transcriptase in hepatocellular carcinoma. Br J Cancer 2000,82(4):833–837CrossRefPubMedGoogle Scholar
  2. 2.
    Lord RV, Salonga D, Danenberg KD, et al. Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg, 2000,4(2):135–142CrossRefPubMedGoogle Scholar
  3. 3.
    Konagi Y, Kabayashi D, Yajima T, et al. Telomerase activity is down regulated via decreases in hTERT but not TEP1 mRNA or hTERC during the differentiation of leukemic cells. Anticancer Res, 2000,20(2A):773–778Google Scholar
  4. 4.
    Watanabe N. Telomerase, cell immortality and cancer Hokkaido Igaku Zasshi, 2001, 76(3):127–132Google Scholar
  5. 5.
    Rhya MS. Telomeres telomerase and immortality. J Natl Cancer Ins, 1995,87(12):884–894CrossRefGoogle Scholar
  6. 6.
    Zou L, Zhang P, Luo C, et al. shRNA targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity. Cancer Chemother Pharmacol, 2006, 57(3):328–334CrossRefPubMedGoogle Scholar
  7. 7.
    Ito H, Kyo S, Kanaya T, et al. Expression of human telomerase subunit and correlation with telomerase activity in urothelial cancer. Clin Cancer Res, 1998,4(7):1603–1608PubMedGoogle Scholar
  8. 8.
    Lancelin F, Anidjar M, Villette JM, et al. Telomerase activity as a potential marker in preneoplastic bladder lesions. BJU Int, 2000,85(4):526–531CrossRefPubMedGoogle Scholar
  9. 9.
    Suzuki T, Suzuki Y, Fujioka T. Expression of the catalytic subunit associated with telomerase gene in human urinary bladder cancer. J Urol, 1999,162(6):2217–2220CrossRefPubMedGoogle Scholar
  10. 10.
    Glasgow JN, Everts M, Curiel DT. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther, 2006,13(9):830–844CrossRefPubMedGoogle Scholar
  11. 11.
    Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22- nucleotide RNAs. Gene Dev, 2001,15(2):188–200CrossRefPubMedGoogle Scholar
  12. 12.
    Oeggerli M, Tomovska S, Schraml P, et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene, 2004, 23(33):5616–5623CrossRefPubMedGoogle Scholar
  13. 13.
    Wu X, Deng Y, Wang G, Tao K. Combining siRNAs at two different sites in the EGFR to suppress its expression, induce apoptosis, and enhance 5-fluorouracil sensitivity of colon cancer cells. J Surg Res, 2007,183(1):56–63CrossRefGoogle Scholar
  14. 14.
    Lin Y, Uemura H, Fujinami K, et al. Telomerase activity in primary prostate cancer. J Urol, 1997,157(3):1161–1165CrossRefPubMedGoogle Scholar
  15. 15.
    Wu KJ, Grandori C, Amacker M, et al. Direct activation of Tert transcription by c-myc. Nature Genet, 1999,21:220–224 (2)CrossRefPubMedGoogle Scholar
  16. 16.
    Suenaga M, Yamaguchi A, Soda H, et al. Antiproliferative effects of Gefitinib are associated with suppression of E2F1 expression and telomerase activity. Anticancer research, 2006,26(5A):3387–3392PubMedGoogle Scholar
  17. 17.
    Pirocanac EC, Nassirpour R, Yang M, et al. Bax-induction gene therapy of pancreatic cancer. J Surg Res, 2002, 106(2):346–351CrossRefPubMedGoogle Scholar
  18. 18.
    Malerba I, Gribaldo L, Diodovich C. Induction of apoptosis and inhibition of telomerase activity in human bone marrow and HL-60 p53 null cells treated with anti-cancer drugs. Toxicology in Vitro, 2005,19(4):523–532CrossRefPubMedGoogle Scholar
  19. 19.
    Sandra Angèle, Alison Falconer, et al. ATM protein overexpression in prostate tumors. Anatomic Pathology, 2004,121(2):231–236Google Scholar
  20. 20.
    David Feldser, Margaret A. Strong, Carol W. Greider, et al. Ataxia telangiectasia mutated (Atm) is not required for telomerase-mediated elongation of short telomerase. Cancer Res, 2003(63):8188–8196Google Scholar
  21. 21.
    Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer, 2003,3(3):155–168CrossRefPubMedGoogle Scholar
  22. 22.
    Metcalfe JA, Parkhill J, Campbell L, et al. Accelerated telomere shortening in ataxia telangiectasia. Nat-Genet, 1996,13(3):350–353CrossRefPubMedGoogle Scholar
  23. 23.
    Greenwell PW, Kronmoal SL, Porter SE. et al. TEL1, a gene involved in controlling telomere length in S. cerevisiae, is homologous to the human ataxia telangiectasia gene. Cell, 1995,82(5):823–829CrossRefPubMedGoogle Scholar
  24. 24.
    DuBois ML, Haimberger ZW, Mclntosh MW, et al. A quantitative assay for telomere protection in Saccharomyces cerevisiae. Genetics, 2002,161(3):995–1013PubMedGoogle Scholar
  25. 25.
    Fujimoto K, Takahashi M. Telomerase activity in human leukemic cell lines is inhibited by antisense pentadecadeoxynucleotides targeted against C-myc mRNA. Biochem Biophys Res Commun, 2007,24(3):775–781Google Scholar
  26. 26.
    Latil A, Vidaud D, Valeri A, et al. hTERT expression correlates with Myc over-expression in human prostate cancer. Int J Cancer, 2000,89(2):172–1797CrossRefPubMedGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Wen Cheng (程 文)
    • 1
  • Zhifeng Wei (位志峰)
    • 1
  • Jianping Gao (高建平)
    • 1
    Email author
  • Zhengyu Zhang (张征宇)
    • 1
  • Jingping Ge (葛京平)
    • 1
  • Kangzhen Jing (景抗震)
    • 1
  • Feng Xu (徐 锋)
    • 1
  • Peng Xie (解 鹏)
    • 1
  1. 1.Department of UrologyJinling HospitalNanjingChina

Personalised recommendations